Cochrane · systematic review · CD011535
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian Emilie, Chaimani Anna, Garcia-Doval Ignacio, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
38
current version
GRADE rated
38
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 6 · 15.8%Low 8 · 21.1%Moderate 20 · 52.6%High 4 · 10.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsAny systemic treatment compared to placebo for chronic plaque psoriasis ‐ PASI 90
Population: people with chronic plaque psoriasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Infliximab Any systemic treatment vs placebo | RR 29.52 [19.94, 43.7] | 5 studies · 1651 participants | Moderate |
Ixekizumab Any systemic treatment vs placebo | RR 28.12 [23.17, 34.12] | 4 studies · 3268 participants | Moderate |
Risankizumab Any systemic treatment vs placebo | RR 27.67 [22.86, 33.49] | 4 studies · 1476 participants | High |
Bimekizumab Any systemic treatment vs placebo | RR 58.64 [3.72, 923.86] | 1 study · 250 participants | Low |
Guselkumab Any systemic treatment vs placebo | RR 25.84 [20.9, 31.95] | 5 studies · 1767 participants | Moderate |
Secukinumab Any systemic treatment vs placebo | RR 23.97 [20.03, 28.7] | 8 studies · 2895 participants | High |
Brodalumab Any systemic treatment vs placebo | RR 21.96 [18.17, 26.53] | 5 studies · 4109 participants | Moderate |
Adalimumab Any systemic treatment vs placebo | RR 17.82 [14.62, 21.72] | 9 studies · 3421 participants | Moderate |
Ustekinumab Any systemic treatment vs placebo | RR 17.17 [14.44, 20.42] | 9 studies · 4231 participants | High |
Tildrakizumab Any systemic treatment vs placebo | RR 17.08 [12.93, 22.56] | 3 studies · 1903 participants | High |
Oral tyrosine kinase 2 (TYK2) inhibitor Any systemic treatment vs placebo | RR 13.99 [1.99, 98.1] | 1 study · 267 participants | Low |
Certolizumab Any systemic treatment vs placebo | RR 12.11 [8.78, 16.71] | 4 studies · 1026 participants | Moderate |
Ciclosporin Any systemic treatment vs placebo | RR 9.88 [5.45, 17.91] | 0 studies · 0 participants | Very low |
Etanercept Any systemic treatment vs placebo | RR 9.72 [8.12, 11.63] | 14 studies · 5650 participants | Moderate |
Methotrexate Any systemic treatment vs placebo | RR 9.78 [7.15, 13.37] | 3 studies · 318 participants | Low |
Tofacitinib Any systemic treatment vs placebo | RR 8.19 [6.53, 10.29] | 5 studies · 3092 participants | Low |
Apremilast Any systemic treatment vs placebo | RR 7.3 [4.26, 12.51] | 5 studies · 2029 participants | Moderate |
Fumaric acid Any systemic treatment vs placebo | RR 3.65 [2.49, 5.36] | 1 study · 704 participants | Very low |
Acitretin Any systemic treatment vs placebo | RR 2.13 [0.37, 12.16] | 0 studies · 0 participants | Very low |
Any systemic treatment compared to placebo for chronic plaque psoriasis ‐ SAEs
Population: people with chronic plaque psoriasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Methotrexate Any systemic treatment vs placebo | RR 0.43 [0.2, 0.95] | 3 studies · 319 participants | Moderate |
Bimekizumab Any systemic treatment vs placebo | RR 0.2 [0.01, 3.16] | 1 study · 250 participants | Low |
Risankizumab Any systemic treatment vs placebo | RR 0.6 [0.37, 0.96] | 4 studies · 1476 participants | Moderate |
Certolizumab Any systemic treatment vs placebo | RR 0.74 [0.31, 1.75] | 4 studies · 1026 participants | Low |
Oral Tyrosine kinase 2 (TYK2) inhibitor Any systemic treatment vs placebo | RR 0.61 [0.06, 5.71] | 1 study · 267 participants | Low |
Tildrakizumab Any systemic treatment vs placebo | RR 0.84 [0.39, 1.83] | 3 studies · 1904 participants | Moderate |
Apremilast Any systemic treatment vs placebo | RR 0.86 [0.48, 1.51] | 6 studies · 2290 participants | Low |
Ustekinumab Any systemic treatment vs placebo | RR 0.89 [0.63, 1.27] | 10 studies · 4553 participants | Moderate |
Etanercept Any systemic treatment vs placebo | RR 0.89 [0.61, 1.31] | 13 studies · 4265 participants | Moderate |
Fumaric acid esters Any systemic treatment vs placebo | RR 0.98 [0.5, 1.94] | 1 study · 704 participants | Very low |
Guselkumab Any systemic treatment vs placebo | RR 0.98 [0.54, 1.79] | 5 studies · 1767 participants | Moderate |
Adalimumab Any systemic treatment vs placebo | RR 0.98 [0.65, 1.49] | 10 studies · 3485 participants | Moderate |
Tofacitinib Any systemic treatment vs placebo | RR 1.01 [0.57, 1.77] | 7 studies · 3122 participants | Moderate |
Brodalumab Any systemic treatment vs placebo | RR 1.04 [0.62, 1.73] | 5 studies · 4109 participants | Moderate |
Infliximab Any systemic treatment vs placebo | RR 1.11 [0.59, 2.07] | 6 studies · 1678 participants | Moderate |
Ixekizumab Any systemic treatment vs placebo | RR 1.09 [0.69, 1.73] | 4 studies · 3268 participants | Moderate |
Ciclosporin Any systemic treatment vs placebo | RR 1.47 [0.19, 11.22] | 0 studies · 0 participants | Very low |
Acitretin Any systemic treatment vs placebo | RR 1.53 [0.19, 12.56] | 0 studies · 0 participants | Very low |
Secukinumab Any systemic treatment vs placebo | RR 1.12 [0.74, 1.7] | 8 studies · 2904 participants | Moderate |